Subcutaneous Biologics Market By Molecule Type (Proteins and Peptides, Monoclonal Antibodies, Nucleic Acid-Based Biologics, Enzymes, Other Biologics), By Therapeutic Application (Metabolic Disorders, Autoimmune and Inflammatory Diseases, Oncology, Neurology, Rare Diseases, Other Applications), By Delivery Format (Prefilled Syringes, Autoinjectors, On-Body Delivery Systems, Large-Volume Injectors, Other Delivery Formats), By End User (Home Care Settings, Hospitals, Oncology Centers, Specialty Clinics), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Subcutaneous Biologics Market: Faster Administration and Home-Based Care Reshape Specialty Medicine

The Global Subcutaneous Biologics Market was valued at USD 124.8 billion in 2025 and is projected to reach approximately USD 219.5 billion by 2032, expanding at a CAGR of 8.4% during 2026–2032, according to internal projections by Strategic Market Research.

 

The subcutaneous biologics market is expanding beyond insulin and autoimmune therapies as companies reformulate complex intravenous biologics into faster clinic- or home-administered injections. Recent FDA approvals for Keytruda Qlex, Sarclisa Escena, and Leqembi Iqlik show the growing use of subcutaneous delivery in oncology and neurology, helping reduce infusion-chair use, nursing time, patient travel, and administration costs.

 

More than 175 subcutaneous biologics are approved, with over 340 candidates in development. Proteins and peptides account for about half of approved products, while monoclonal antibodies represent a major reformulation opportunity. Pipeline activity is increasingly focused on high-concentration formulations, hyaluronidase co-formulations, autoinjectors, and on-body delivery systems that can shift higher-dose therapies away from intravenous infusion.

 

Redefining Market Boundaries and Commercial Dynamics

The subcutaneous biologics market is moving beyond its traditional dependence on insulin and chronic autoimmune therapies. Pharmaceutical companies are increasingly reformulating monoclonal antibodies and other large-molecule medicines that were previously administered through intravenous infusion. The commercial objective is to shorten administration time, reduce pressure on infusion centres, improve patient convenience, and extend the competitiveness of established biologic franchises.

More than 175 subcutaneous biologics are approved, while over 340 candidates are progressing through the clinical pipeline. Proteins and peptides account for roughly 50% of approved products, equal to approximately 88 of the 175-product approval base, while monoclonal antibodies form the second-largest and most commercially important reformulation category. The market includes these therapeutic products alongside high-concentration technologies, permeation-enhancing enzymes, prefilled syringes, autoinjectors, on-body delivery systems, and licensing agreements between pharmaceutical manufacturers and delivery-platform companies.

Subcutaneous administration can reduce the time patients spend in hospitals, although actual savings depend on medicine pricing, reimbursement policy, device cost, treatment frequency, and whether administration can be transferred completely into the home. Its strongest commercial value is found in recurring treatments where infusion-chair capacity, nursing time, patient travel, and hospital operating costs create measurable financial pressure.

 

Two Revenue Engines Are Defining the Market

Market expansion is developing through two distinct business models. The first is the high-volume chronic treatment market, supported by insulin, incretin-based metabolic therapies, and self-administered biologics for inflammatory diseases. The second is the conversion of high-value intravenous antibodies into shorter subcutaneous regimens, particularly in oncology.

Metabolic treatments generate the highest injection frequency because medicines may be administered daily or weekly across large patient populations. They represent about 30% of protein-based subcutaneous biologics within the supplied approval landscape. The United States had an estimated 40.1 million people with diagnosed or undiagnosed diabetes in 2023, including approximately 2.1 million people with diagnosed type 1 diabetes. This population supports recurring demand for injection pens, prefilled syringes, autoinjectors, and related fill-finish manufacturing capacity.

Immunology represents a mature premium-biologic segment. Sanofi reported 2025 Dupixent sales of EUR 15.71 billion, up 25.2% at constant exchange rates. Based on the company’s reported figures, Dupixent accounted for approximately 36% of Sanofi’s EUR 43.63 billion total 2025 sales. AbbVie reported USD 17.56 billion in Skyrizi revenue, up 49.9% year over year and equal to nearly 58% of its USD 30.41 billion immunology portfolio. These figures demonstrate the revenue scale that self-administered biologics can achieve when they address multiple chronic indications and maintain broad reimbursement coverage.

 

Oncology Is Becoming the Main IV-to-SC Conversion Opportunity

Recent regulatory decisions show that subcutaneous delivery is becoming an important component of oncology product management. These formulations can reduce administration from several hours to a few minutes while retaining the clinical activity and systemic exposure of the corresponding intravenous medicine.

The FDA approved Tecentriq Hybreza in September 2024 for the adult indications covered by intravenous atezolizumab. Its 15 mL dose can be administered in approximately seven minutes every three weeks. Opdivo Qvantig followed in December 2024, while Keytruda Qlex was approved in September 2025, widening the competitive importance of administration convenience among leading immune-checkpoint inhibitor franchises.

Johnson & Johnson’s Rybrevant Faspro received FDA approval in December 2025 across indications previously treated with intravenous amivantamab. In PALOMA-3, systemic administration reactions occurred in 13% of patients receiving the subcutaneous formulation, compared with infusion-related reactions in 66% of patients receiving intravenous treatment. Sanofi’s Sarclisa Escena was approved in July 2026 with both manual administration and the CirCLIQ on-body delivery system.

The commercial value attached to oncology conversion is visible in franchise revenue. Johnson & Johnson reported USD 14.35 billion in 2025 DARZALEX sales, up 23.0% and equivalent to approximately 56.5% of its USD 25.38 billion oncology portfolio. Sanofi’s Sarclisa sales reached EUR 588 million in 2025, increasing 28.5% before the US subcutaneous launch. These approvals allow oncology centres to treat more patients with the same infusion-chair capacity while giving manufacturers an additional route to defend mature brands.

 

Formulation Capacity Has Become a Competitive Asset

Conventional syringes and autoinjectors can accommodate only limited liquid volumes. Standard products have historically been designed around approximately 1–2 mL, although some newer formats can deliver around 3 mL. Fitting an intravenous-sized biologic dose into this volume frequently requires a higher drug concentration, which can create viscosity, stability, manufacturing, and injection-force challenges.

High-concentration platforms reduce the liquid volume required to deliver a therapeutic dose. Recombinant hyaluronidase temporarily reduces resistance within the tissue matrix, enabling larger volumes to spread beneath the skin. On-body systems administer medicines more slowly over several minutes or longer, reducing the pressure associated with rapid large-volume injection.

Halozyme’s ENHANZE platform has become commercially significant because it is used to reformulate multiple high-value antibodies. The company reported ten approved ENHANZE-based products and 13 collaboration agreements in its 2025 filing and expanded into technologies intended to support concentrations of up to approximately 500 mg/mL.

Platform licensing is creating a separate revenue stream alongside pharmaceutical sales. Halozyme generated USD 867.8 million in royalty revenue during 2025, up 52% from USD 571.0 million in 2024. Royalties represented approximately 62% of its USD 1.40 billion total revenue. DARZALEX contributed USD 482.7 million, VYVGART Hytrulo USD 157.2 million, and Phesgo USD 105.6 million; together, these three products accounted for approximately 86% of royalty revenue. Halozyme expects 2026 royalty revenue of USD 1.13–1.17 billion, representing 30%–35% annual growth.

 

Delivery Devices Are Expanding Beyond Standard Autoinjectors

Prefilled syringes and autoinjectors remain the principal formats for conventional low-volume subcutaneous biologics. Prefilled syringes account for approximately 78% of physical subcutaneous biologic injection volume in the supplied device landscape, while disposable single-use products represent more than 95% of distributed devices. These figures describe unit volume rather than drug-revenue share.

Large-dose biologics require a different device category. Wearable and on-body delivery systems can accommodate considerably more liquid than conventional autoinjectors, with several platforms designed for approximately 5–20 mL and selected mechanical or patch-pump systems reaching around 9–23 mL. Their commercial opportunity is expanding as pharmaceutical companies move higher-dose antibodies and long-acting medicines away from infusion centres.

The FDA’s approval of a home-administered subcutaneous Leqembi regimen illustrates how this delivery route is entering disease areas previously dependent on infusion infrastructure. Home administration does not eliminate clinical oversight; lecanemab continues to require appropriate patient selection and MRI monitoring.

Device suppliers are increasingly evaluated on dose accuracy, injection force, reliability, compatibility with viscous formulations, and manufacturing scalability. Up to 30% of specialty biologic injection volume is estimated to be migrating from traditional clinical settings toward patient homes, increasing demand for prefilled, automated, and connected formats.

 

Biosimilars and Payer Pressure Are Reshaping Pricing

Subcutaneous delivery can improve treatment workflow, but it does not permanently protect a biologic from price competition. NHS England expected to save approximately GBP 300 million through its adalimumab procurement programme. More than 46,000 patients were receiving adalimumab, while competition among four biosimilar manufacturers reduced the expected purchasing cost to roughly one-quarter of the previous annual expenditure of more than GBP 400 million.

US pricing pressure is also increasing. Under Medicare’s negotiated prices for 2026, Enbrel’s agreed price for a 30-day supply was USD 2,355 compared with a 2023 list price of USD 7,106, a 67% reduction. Stelara’s negotiated price was USD 4,695 compared with USD 13,836, a 66% reduction. CMS reported 2023 Part D gross covered costs of approximately USD 2.95 billion for Enbrel and USD 2.99 billion for Stelara.

Manufacturers are responding through improved devices, less frequent dosing schedules, additional indications, high-concentration formulations, and patient-support services. Biosimilar developers are also competing through reduced injection discomfort, device usability, dependable supply, and contracting terms.

 

Market Segmentation Highlights

By molecule type, proteins and peptides account for roughly half of approved subcutaneous biologics and the highest injection frequency. Monoclonal antibodies represent the strongest strategic growth opportunity because high-revenue products in oncology, immunology, neurology, and rare diseases are being converted from intravenous to subcutaneous delivery.

By therapeutic application, metabolic disorders lead recurring unit demand and account for around 30% of protein-based subcutaneous approvals. Autoimmune and inflammatory diseases form the most established self-administration market, supported by Dupixent and Skyrizi revenues and annual growth of 25.2% and 49.9%, respectively. Oncology is producing the fastest visible wave of intravenous-to-subcutaneous reformulation, while neurology is emerging through Alzheimer’s disease, multiple sclerosis, migraine, and antibody-based treatments.

By delivery format, prefilled syringes lead physical volume with an estimated 78% share, while autoinjectors remain important for simplified home administration. On-body delivery systems and large-volume injectors hold a smaller unit share but are expected to outgrow standard formats as they extend subcutaneous delivery to larger doses.

By end user, home care and patient self-administration are expanding, with up to 30% of specialty biologic injection volume moving outside traditional infusion settings. Hospitals, oncology centres, and specialist clinics will remain important for treatment initiation, adverse-event observation, complex regimens, and medicines requiring imaging or laboratory monitoring.

 

Regional Commercial Outlook

North America holds the leading commercial position. The United States accounts for roughly 50% of active global patient utilization for approved subcutaneous biologics and nearly 65% of the formulation-technology development landscape in the supplied regional data. Its high specialty-drug expenditure, large chronic-disease population, and concentration of platform developers support this lead.

Europe combines adoption of subcutaneous oncology formulations with strong biosimilar procurement. National health systems can capture savings from shorter administration and lower nursing requirements, but centralised purchasing also creates intense pressure on medicine prices.

Asia-Pacific presents the strongest expansion opportunity as chronic-disease treatment, insurance coverage, biologic manufacturing, and regulatory capacity increase. Adoption will vary by country because reimbursement, cold-chain infrastructure, device affordability, and approval pathways remain uneven.

 

Competitive and Strategic Outlook for 2026–2032

Subcutaneous administration is becoming a product-development and lifecycle-management strategy rather than a secondary delivery option. Chronic self-injected therapies will continue to generate the largest treatment volumes, while converted monoclonal antibodies are likely to produce the most valuable formulation, device, and licensing opportunities.

The market’s projected increase from USD 124.8 billion in 2025 to USD 219.5 billion by 2032 represents approximately USD 94.7 billion in additional annual revenue opportunity at an 8.4% CAGR. The strongest competitive positions will belong to companies that coordinate the biologic molecule, formulation, delivery device, manufacturing process, regulatory strategy, and reimbursement evidence as one commercial programme.

Oncology conversions, high-concentration technologies, hyaluronidase-enabled formulations, and wearable large-volume devices are expanding the addressable market beyond traditional 1–2 mL injections. At the same time, biosimilar entry and government price negotiations will limit the ability of mature brands to depend on historical pricing. Subcutaneous biologics that demonstrate measurable operating savings, dependable home administration, suitable monitoring pathways, and meaningful differentiation are positioned to capture the strongest demand through 2032.

 

Subcutaneous Biologics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 124.8 Billion
Revenue Forecast in 2032	USD 219.5 Billion
Overall Growth Rate	CAGR of 8.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Molecule Type, By Therapeutic Application, By Delivery Format, By End User, By Geography
By Molecule Type	Proteins and Peptides, Monoclonal Antibodies, Nucleic Acid-Based Biologics, Enzymes, Other Biologics
By Therapeutic Application	Metabolic Disorders, Autoimmune and Inflammatory Diseases, Oncology, Neurology, Rare Diseases, Other Applications
By Delivery Format	Prefilled Syringes, Autoinjectors, On-Body Delivery Systems, Large-Volume Injectors, Other Delivery Formats
By End User	Home Care Settings, Hospitals, Oncology Centers, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Switzerland, Netherlands, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of self-administered biologics, increasing conversion of intravenous biologics to subcutaneous formulations, growing demand for home-based specialty care, expansion of high-concentration biologic formulations, adoption of autoinjectors and on-body delivery systems, increasing chronic disease burden, and pressure to reduce infusion-centre utilization
Customization Option	Available upon request